-
公开(公告)号：US10537550B2
公开(公告)日：2020-01-21
申请号：US12189598
申请日：2008-08-11
Applicant: Joachim Goede , Joachim Maus , Peter Jürgen Cnota , Istvan Szelenyi
Inventor： Joachim Goede , Joachim Maus , Peter Jürgen Cnota , Istvan Szelenyi
IPC: A61K31/401 , A61K31/4015 , A61K31/573
Abstract: The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the NOVOLIZER®.
-
2.发明授权Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory disease 有权抗胆碱能药物与4型磷酸二酯酶抑制剂的组合用于治疗呼吸系统疾病公开(公告)号：US08097605B2
公开(公告)日：2012-01-17
申请号：US12365003
申请日：2009-02-03
Applicant: Joachim Maus , Peter Juergen Cnota , Istvan Szelenyi , Beatrix Fyrnys
Inventor： Joachim Maus , Peter Juergen Cnota , Istvan Szelenyi , Beatrix Fyrnys
CPC classification number: A61K31/44 , A61K9/0073 , A61K31/40 , A61K31/401 , A61K31/4015 , A61K31/4439 , A61K31/519 , A61K45/06 , Y10S514/826 , A61K2300/00
Abstract: The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R,R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.
Abstract translation: 本发明涉及吸入/口服PDE4抑制剂与吸入的抗胆碱能支气管扩张剂（毒蕈碱受体拮抗剂），优选Roflumilast或AWD-12-281和R，R-格隆溴铵的组合，用于呼吸系统疾病的症状或预防性治疗 ，特别是伴有阻塞性或炎症性疾病如慢性阻塞性肺疾病（COPD）或哮喘的患者。 它还包括在局部施用（吸入）制剂中和在吸入装置中的应用中呈现这种组合，例如在Novolizer中。
-
3.发明授权Combination of anticholineric and β mimetics for the treatment of respiratory diseases 有权抗胆碱药与组合 用于治疗呼吸系统疾病的模拟物质公开(公告)号：US07985766B2
公开(公告)日：2011-07-26
申请号：US11882109
申请日：2007-07-30
Applicant: Joachim Goede , Joachim Maus , Peter Jurgen Cnota , Istvan Szelenyi
Inventor： Joachim Goede , Joachim Maus , Peter Jurgen Cnota , Istvan Szelenyi
IPC: A61K31/4015 , A61K31/167
CPC classification number: A61K45/06 , A61K9/0075 , A61K9/008 , A61K31/138 , A61K31/167 , A61K31/401 , A61K31/4015 , A61K2300/00
Abstract: The present invention describes a combination of an anticholinergic, such as R,R-glycopyrrolate, and a β mimetic, such as tormoterol, for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma.
Abstract translation: 本发明描述了抗胆碱能药物如R，R-格隆溴铵和一种bgr的组合; 模拟物，如泰莫曲醇，用于治疗呼吸道疾病，包括呼吸道炎症或梗阻，如慢性阻塞性肺疾病（COPD）和哮喘。
-
公开(公告)号：US07553858B2
公开(公告)日：2009-06-30
申请号：US11002762
申请日：2004-12-03
Applicant: Istvan Szelenyi , Joachim Maus , Peter J. Cnota
Inventor： Istvan Szelenyi , Joachim Maus , Peter J. Cnota
IPC: A61K31/44 , A61K31/135
CPC classification number: A61K31/137 , A61K31/445 , A61K2300/00
Abstract: The subject of the present invention is to provide a combination of two centrally acting analgesics, flupirtine and tramadol, or their respective pharmaceutically acceptable salts for the treament of pain.
Abstract translation: 本发明的主题是提供两种中枢作用的止痛剂，氟吡汀和曲马多或其各自的药学上可接受的盐用于疼痛的组合。
-
5.发明申请Combination of Anticholinergics and Inhibitors of Phosphodiesterase Type 4 For The Treatment of Respiratory Disease 有权抗胆碱能药物与4型磷酸二酯酶抑制剂联合用于治疗呼吸系统疾病公开(公告)号：US20090136429A1
公开(公告)日：2009-05-28
申请号：US12365003
申请日：2009-02-03
Applicant: Joachim Maus , Peter Juergen Cnota , Istvan Szelenyi , Beatrix Fyrnys
Inventor： Joachim Maus , Peter Juergen Cnota , Istvan Szelenyi , Beatrix Fyrnys
IPC: A61K9/12 , A61K31/44 , A61P11/06 , A61K31/4015
CPC classification number: A61K31/44 , A61K9/0073 , A61K31/40 , A61K31/401 , A61K31/4015 , A61K31/4439 , A61K31/519 , A61K45/06 , Y10S514/826 , A61K2300/00
Abstract: The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R, R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.
Abstract translation: 本发明涉及吸入/口服PDE4抑制剂与吸入的抗胆碱能支气管扩张剂（毒蕈碱受体拮抗剂），优选Roflumilast或AWD-12-281和R，R-格隆溴铵的组合，用于呼吸系统疾病的症状或预防性治疗 ，特别是伴有阻塞性或炎症性疾病如慢性阻塞性肺疾病（COPD）或哮喘的患者。 它还包括将这种组合在局部施用（吸入）制剂中的应用和例如在Novolizer中的吸入装置中的应用。
-
Patent Agency Ranking
6.发明申请Combination of Anticholinergics and Glucocorticoids for the Long-Term Treatment of Asthma and COPD 审中-公开组合抗胆碱能药物和糖皮质激素用于长期治疗哮喘和COPD公开(公告)号：US20080300226A1
公开(公告)日：2008-12-04
申请号：US12189598
申请日：2008-08-11
Applicant: Joachim Goede , Joachim Maus , Peter Jurgen Cnota , Istvan Szelenyi
Inventor： Joachim Goede , Joachim Maus , Peter Jurgen Cnota , Istvan Szelenyi
Abstract: The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.
Abstract translation: 本发明描述了包含抗胆碱能成分和糖皮质激素成分的局部吸入药物制剂的组合及其在对呼吸道疾病的症状和预防性治疗中的用途，特别是阻塞性成分或潜在炎症如哮喘和慢性阻塞性肺病 （COPD）。 它还包括将这种组合在局部施用（吸入）制剂中的应用和例如在Novolizer中的吸入装置中的应用。
-
7.发明申请Novel combination of anticholinergics - B2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases 有权抗胆碱能药物 - B2-肾上腺素受体激动剂，抗白三烯（白三烯受体拮抗剂），用于治疗炎性疾病的糖皮质激素和/或磷酸二酯酶4抑制剂的新型组合公开(公告)号：US20070196285A1
公开(公告)日：2007-08-23
申请号：US11642967
申请日：2006-12-21
Applicant: Joachim Maus , Horst Kastrup , Istvan Szelenyi , Peter Cnota , Artur Bauhofer
Inventor： Joachim Maus , Horst Kastrup , Istvan Szelenyi , Peter Cnota , Artur Bauhofer
IPC: A61K31/573 , A61K31/47 , A61K9/14 , A61K31/138 , A61K31/4015
CPC classification number: A61K31/40 , A61K9/0075 , A61K9/008 , A61K31/167 , A61K31/4015 , A61K31/58 , A61K45/06 , A61K2300/00
Abstract: The invention relates to novel combinations based on anticholinergics, β2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.
Abstract translation: 本发明涉及基于抗胆碱能药物，β2 - 肾上腺素能受体激动剂，PDE 4抑制剂，糖皮质激素和白三烯受体拮抗剂的新型组合，其制备方法及其用于治疗炎性疾病，优选 呼吸系统疾病，如支气管哮喘和慢性阻塞性肺疾病（COPD）或风湿性或自身免疫性疾病。
-
8.发明申请Treatment of rhinitis with anticholinergics alone or in combination with antihistamines, phosphodiesterase 4 inhibitors, or corticosteroids 审中-公开单用抗胆碱能药物或与抗组胺药，磷酸二酯酶4抑制剂或皮质类固醇联合治疗鼻炎公开(公告)号：US20050222102A1
公开(公告)日：2005-10-06
申请号：US11051470
申请日：2005-02-07
Applicant: Joachim Maus , Ursula Petzold , Istvan Szelenyi , Torsten Hoffmann , Mario Weingart
Inventor： Joachim Maus , Ursula Petzold , Istvan Szelenyi , Torsten Hoffmann , Mario Weingart
IPC: A61K31/401 , A61K31/519 , A61K31/55 , A61K31/573 , A61K39/00 , A61K45/06
CPC classification number: A61K45/06 , A61K31/401 , A61K31/519 , A61K31/55 , A61K31/573 , A61K2300/00
Abstract: The present invention provides novel combinations comprising a topical anticholinergic drug alone or in combination with topically administered antihistamines, topically or orally administered phosphodiesterase 4 inhibitors or topical corticosteroids for the treatment of rhinitis of various origins. It further comprises presentation of these combinations in locally applied formulations and includes various pharmaceutical formulations suitable for topical application, e.g. nasal sprays, nasal drops, emulsions, pastes, creams and gels.
Abstract translation: 本发明提供新颖的组合，其包括单独的局部抗胆碱能药物或局部施用的抗组胺剂，局部或口服给予的磷酸二酯酶4抑制剂或局部皮质类固醇用于治疗各种原因的鼻炎。 其还包括在局部施用的制剂中呈现这些组合，并且包括适用于局部应用的各种药物制剂，例如。 鼻喷雾剂，滴鼻剂，乳剂，糊剂，霜剂和凝胶剂。
-
9.发明申请Combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD 审中-公开组合抗胆碱能药物和糖皮质激素用于长期治疗哮喘和COPD公开(公告)号：US20050175548A1
公开(公告)日：2005-08-11
申请号：US11051468
申请日：2005-02-07
Applicant: Joachim Goede , Joachim Maus , Peter Cnota , Istvan Szelenyi
Inventor： Joachim Goede , Joachim Maus , Peter Cnota , Istvan Szelenyi
IPC: A61K31/401 , A61K31/4015 , A61K31/56 , A61K31/573 , A61K45/06 , A61L9/04
CPC classification number: A61K31/401 , A61K31/4015 , A61K31/56 , A61K31/573 , A61K45/06 , A61K2300/00
Abstract: The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.
Abstract translation: 本发明描述了包含抗胆碱能成分和糖皮质激素成分的局部吸入药物制剂的组合及其在对呼吸道疾病的症状和预防性治疗中的用途，特别是阻塞性成分或潜在炎症如哮喘和慢性阻塞性肺病 （COPD）。 它还包括将这种组合在局部施用（吸入）制剂中的应用和例如在Novolizer中的吸入装置中的应用。
-
10.发明授权Combination of anticholinergics, β2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases 有权抗胆碱能药，β2-肾上腺素能受体激动剂，抗白细胞三烯（白三烯受体拮抗剂），糖皮质激素和/或磷酸二酯酶4抑制剂用于治疗炎性疾病公开(公告)号：US08518918B2
公开(公告)日：2013-08-27
申请号：US13242241
申请日：2011-09-23
Applicant: Joachim Maus , Kastrup Horst , Istvan Szelenyi , Peter Jurgen Cnota , Bauhofer Artur
Inventor： Joachim Maus , Kastrup Horst , Istvan Szelenyi , Peter Jurgen Cnota , Bauhofer Artur
IPC: A61K31/56 , A61K31/16 , A61K31/40 , A61K31/135
CPC classification number: A61K31/40 , A61K9/0075 , A61K9/008 , A61K31/167 , A61K31/4015 , A61K31/58 , A61K45/06 , A61K2300/00
Abstract: The invention relates to novel combinations based on anticholinergics, β2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.
Abstract translation: 本发明涉及基于抗胆碱能药物，β2-肾上腺素能受体激动剂，PDE4抑制剂，糖皮质激素和白三烯受体拮抗剂的新型组合，其生产方法及其用于治疗炎性疾病，优选呼吸系统疾病作为支气管哮喘和慢性阻塞性 肺部疾病（COPD）或风湿性或自身免疫性疾病。
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.02 seconds)
